TKT and glioblastoma: In summary, we demonstrate the potential to genetically modify cAd-MSCs with a lentiviral vector efficiently to express the herpes simplex virus TK and that in combination with GCV prodrug demonstrated effective antitumor potential on U-87 glioblastoma cell line in vitro and in vivo mice model.